Immunocore Holdings plc
NASDAQ:IMCRBiotechnology
+$0.18 today
- Market cap
- $1.42B
- Beta
- 0.75
- P/E (TTM)
- -77.5
- EPS (TTM)
- -$0.37
Volume 0.30M
Average 0.40M
IMCR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Immunocore Holdings plcNASDAQ: IMCR
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA grows, but more slowly than its trailing trend
Q1 FY2026 EBITDA of $16.53M rose 65.9% year over year, behind the +2711.1% change in trailing-twelve-month EBITDA.
Context
- EBITDA amounted to 0.1% of revenue in FY2025, down 15.4 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 11 analysts of -$145.76M (-37746.2%) for the fiscal year ending Dec 2026, a slowdown from the +101.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $16.53M+305.7% QoQ
- Last fiscal yearDec 2025
- $387.18K+101.0% YoY
- LTMMar 2026
- $6.24M+2711.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +65.9% | -460.9% | -526.8 pp |
| 1 year | +101.0% | -37746.2% | -37847.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
Mixed currencies · from the income statement
- Latest · FY2025
- 387.18K USD
- Year-over-year change
- +101.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 387.18K | +101.0% |
| FY2024 | 2024-12-31 | (38.5M) | — |
| FY2023 | 2023-12-31 | (40.87M) | -6.6% |
| FY2022 | 2022-12-31 | (38.35M) | +69.0% |
| FY2021 | 2021-12-31 | (123.58M) | — |
EBITDA vs competitors
How IMCR compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +2711.1% is the highest of 11, against a peer median of -44.9%.
- EBITDA amounts to 1.6% of revenue for IMCR, versus a peer median of 439.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.88M USD | +463.6% | — | 48.0% | |
| LTM Mar 2026 | $6.24M USD | +2711.1% | — | 1.6% | |
| FY2025 | -€43.65M EUR | +7.0% | — | 1566.1% | |
| LTM Mar 2026 | -$50.64M USD | -7.0% | — | 32.2% | |
| FY2025 | -A$62.88M AUD | -41.2% | — | 1246.6% | |
| LTM Mar 2026 | -$112.45M USD | -48.6% | — | 520.3% | |
| LTM Jun 2026 | -$123.6M USD | -14.3% | — | 117.7% | |
| LTM Mar 2026 | -€202.4M EUR | -4407.9% | — | 542.7% | |
| LTM Jun 2026 | -$419M USD | -48.6% | — | 358.1% | |
| LTM Jun 2026 | -€941.06M EUR | -2167.6% | — | 35.6% | |
| LTM Sep 2026 | -$1.01B USD | -332.3% | — | 550.8% | |
| Peer median (excluding IMCR) | — | -44.9% | — | 439.2% | |
Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 27.04M | 144.23M | 197.39M | 247.98M | 297.57M |
| Cost of Revenue | 0 | 5.29M | 820.63K | 5.54M | 6.21M |
| Gross Profit | 27.04M | 138.94M | 196.57M | 242.44M | 291.36M |
| Gross Margin | 100.0% | 96.3% | 99.6% | 97.8% | 97.9% |
| Research & Development | 74.31M | 84.31M | 129.42M | 177.44M | 204.47M |
| Selling, General & Admin | 82.15M | 0 | 114.35M | 121.17M | 120.62M |
| Operating Expenses | 156.46M | 181.71M | 243.77M | 298.77M | 325.09M |
| Depreciation & Amortization | 5.63M | 4.41M | 3.24M | 3.36M | 2.43M |
| EBITDA | (123.58M) | (38.35M) | (40.87M) | (38.5M) | 387.18K |
| EBITDA Margin | -457.0% | -26.6% | -20.7% | -15.5% | 0.1% |
| Operating Income | (129.42M) | (42.77M) | (47.2M) | (56.28M) | (33.74M) |
| Operating Margin | -478.5% | -29.7% | -23.9% | -22.7% | -11.3% |
| Interest Income | 65K | 3.76M | 14.23M | 25.62M | 16.48M |
| Interest Expense | 5.57M | 5.41M | 4.08M | 18.84M | 12.17M |
| Other Income / Expenses | (3.92M) | 8.95M | (982.07K) | 14.01M | 19.53M |
| Income Before Tax | (133.34M) | (33.82M) | (48.19M) | (42.32M) | (14.21M) |
| Pre-Tax Margin | -493.0% | -23.4% | -24.4% | -17.1% | -4.8% |
| Income Tax Expense | 111.19K | 9.65M | (4.43M) | (1.48M) | 12.21M |
| Net Income | (133.45M) | (43.46M) | (43.75M) | (40.81M) | (26.42M) |
| Net Margin | -493.4% | -30.1% | -22.2% | -16.5% | -8.9% |
| EPS (Basic) | (3.13) | (0.95) | (0.89) | (1.02) | (0.53) |
| EPS (Diluted) | (3.00) | (0.95) | (0.89) | (1.02) | (0.53) |
| Weighted Avg Shares | 42.49M | 45.71M | 48.89M | 49.99M | 50.35M |
| Weighted Avg Shares (Diluted) | 43.86M | 45.71M | 48.89M | 49.99M | 50.35M |
Immunocore Holdings plc
NASDAQ:IMCR
Intrinsic Alpha fair value
Locked
Current Price
$27.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.